Literature DB >> 6677563

Prognostic factors in patients with subdiaphragmatic Hodgkin's disease.

P Mauch, H Greenberg, A Lewin, J R Cassady, R Weichselbaum, S Hellman.   

Abstract

Between April 1969 and December 1980, 329 patients with pathologically staged IA-IIB Hodgkin's disease were treated at the Joint Center for Radiation Therapy. Twenty-five (7.6 per cent) of these patients presented with inguinal-femoral or superficial iliac adenopathy and had disease limited to below the diaphragm. In addition 11 patients presented with intra-abdominal masses and Hodgkin's disease was diagnosed on laparotomy. The median age, histologic subtypes, and actuarial relapse free and overall survival of patients with peripheral adenopathy limited to below the diaphragm were similar to patients with supradiaphragmatic Hodgkin's disease. Patients with disease limited to the pelvic or inguinal-femoral nodes were treated with pelvic and para-aortic irradiation alone. Staging laparotomy identified those patients with para-aortic or splenic involvement and these patients were treated with total nodal irradiation or combined modality treatment. The small group of patients who presented with intra-abdominal disease without peripheral adenopathy was older, had a predominance of lymphocyte depleted histology, and had a worse prognosis than the other patients described.

Entities:  

Mesh:

Year:  1983        PMID: 6677563     DOI: 10.1002/hon.2900010303

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  1 in total

1.  Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT.

Authors:  Cédric Rossi; Morgane Mounier; Pauline Brice; Violaine Safar; Emmanuelle Nicolas-Virelizier; Philippe Rey; Aspasia Stamatoullas-Bastard; Marion Alcantara; Adrien Chauchet; Emilie Reboursière; Lauriane Filliatre; Aurore Perrot; Sylvain Garciaz; Gilles Salles; Bertrand Coiffier; Hervé Ghesquières; René-Olivier Casasnovas
Journal:  Oncotarget       Date:  2017-07-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.